

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6

	T300+D (n = 75)	D (n = 104)	T (n = 69)	T75+D (n = 84)
OS, months, median (95% CI)	18.73 (10.78-27.27)	13.57 (8.74-17.64)	15.11 (11.33-20.50)	11.30 (8.38-14.95)
Survival Rate				
12 months (95% CI), %	60.3 (47.9-70.6)	51.2 (40.8-60.8)	60.2 (47.3-70.9)	49.2 (37.9-59.6)
18 months (95% CI), %	52.0 (38.9-63.6)	35.3 (25.0-45.8)	45.7 (32.8-57.7)	34.7 (24.4-45.2)
Total treatment duration, months, median (range)	3.7 (0.8-27.1)	3.7 (0.7-34.3)	3.7 (0.9-31.2)	2.4 (0.6-31.4)

FIGURE 7




FIGURE 7 (continued)




FIGURE 8

	T300+D (n = 75)	D (n = 104)	T (n = 69)	T75+D (n = 84)
Objective Response Rate (95% CI) ^a	24.0 (14.9-35.3)	10.6 (5.4-18.1)	7.2 (2.4-16.1)	9.5 (4.2-17.9)
CR	1 (1.3)	0	0	2 (2.4)
PR	17 (22.7)	11 (10.6)	5 (7.2)	6 (7.1)
SD	16 (21.3)	28 (26.9)	29 (42.0)	23 (27.4)
Disease Control Rate, n (%)	34 (45.3)	39 (37.5)	34 (49.3)	31 (36.9)
Median Duration of Response, ^b months	NR	11.17	23.95	13.21
Median Time to Response, months	1.86	3.65	1.81	2.86
PFS, months, median (95% CI)	2.17 (1.91-5.42)	2.07 (1.84-2.83)	2.69 (1.87-5.29)	1.87 (1.77-2.43)

FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 15 (continued)




FIGURE 16





FIGURE 16 (continued)



Cut point was median number (shown above) of expanded clones per arm